These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 30085126)

  • 41. Inverse agonism at beta-adrenergic receptors: therapeutic implications.
    Gurdal H
    Expert Rev Neurother; 2002 Mar; 2(2):261-9. PubMed ID: 19811007
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Protean agonism at histamine H3 receptors in vitro and in vivo.
    Gbahou F; Rouleau A; Morisset S; Parmentier R; Crochet S; Lin JS; Ligneau X; Tardivel-Lacombe J; Stark H; Schunack W; Ganellin CR; Schwartz JC; Arrang JM
    Proc Natl Acad Sci U S A; 2003 Sep; 100(19):11086-91. PubMed ID: 12960366
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inverse agonism or neutral antagonism at G-protein coupled receptors: a medicinal chemistry challenge worth pursuing?
    Greasley PJ; Clapham JC
    Eur J Pharmacol; 2006 Dec; 553(1-3):1-9. PubMed ID: 17081515
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Techniques for studying inverse agonist activity of antidepressants at recombinant nonedited 5-HT(₂C-INI) receptor and native neuronal 5-HT(₂C) receptors.
    Seimandi M; Bockaert J; Marin P
    Methods Enzymol; 2010; 485():61-79. PubMed ID: 21050911
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Signal transduction mechanism of biased ligands at histamine H2 receptors.
    Alonso N; Monczor F; Echeverría E; Davio C; Shayo C; Fernández N
    Biochem J; 2014 Apr; 459(1):117-26. PubMed ID: 24417223
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Deciphering biased inverse agonism of cangrelor and ticagrelor at P2Y
    Garcia C; Maurel-Ribes A; Nauze M; N'Guyen D; Martinez LO; Payrastre B; Sénard JM; Galés C; Pons V
    Cell Mol Life Sci; 2019 Feb; 76(3):561-576. PubMed ID: 30406277
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vivo bidirectional modulatory effect of benzodiazepine receptor ligands on GABAergic transmission evaluated by positron emission tomography in non-human primates.
    Brouillet E; Chavoix C; Bottlaender M; Khalili-Varasteh M; Hantraye P; Fournier D; Dodd RH; Mazière M
    Brain Res; 1991 Aug; 557(1-2):167-76. PubMed ID: 1660750
    [TBL] [Abstract][Full Text] [Related]  

  • 48. TSH receptor monoclonal antibodies with agonist, antagonist, and inverse agonist activities.
    Sanders J; Miguel RN; Furmaniak J; Smith BR
    Methods Enzymol; 2010; 485():393-420. PubMed ID: 21050929
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Functional partial agonism at cloned human muscarinic acetylcholine receptors.
    Bräuner-Osborne H; Ebert B; Brann MR; Falch E; Krogsgaard-Larsen P
    Eur J Pharmacol; 1996 Oct; 313(1-2):145-50. PubMed ID: 8905341
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Assessment of inverse agonism for the angiotensin II type 1 receptor.
    Akazawa H; Yasuda N; Miura S; Komuro I
    Methods Enzymol; 2010; 485():25-35. PubMed ID: 21050909
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A pharmacological primer of biased agonism.
    Andresen BT
    Endocr Metab Immune Disord Drug Targets; 2011 Jun; 11(2):92-8. PubMed ID: 21476970
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Conceptual and experimental issues in biased agonism.
    Onaran HO; Costa T
    Cell Signal; 2021 Jun; 82():109955. PubMed ID: 33607257
    [TBL] [Abstract][Full Text] [Related]  

  • 53. How inverse can a neutral antagonist be? Strategic questions after the rimonabant issue.
    Giraldo J
    Drug Discov Today; 2010 Jun; 15(11-12):411-5. PubMed ID: 20447467
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A robust and high-capacity [(35)S]GTPgammaS binding assay for determining antagonist and inverse agonist pharmacological parameters of histamine H(3) receptor ligands.
    Miller TR; Baranowski JL; Estvander BR; Witte DG; Carr TL; Manelli AM; Krueger KM; Cowart MD; Brioni JD; Esbenshade TA
    Assay Drug Dev Technol; 2008 Jun; 6(3):339-49. PubMed ID: 18593375
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Analysis of agonism and inverse agonism in functional assays with constitutive activity: estimation of orthosteric ligand affinity constants for active and inactive receptor states.
    Ehlert FJ; Suga H; Griffin MT
    J Pharmacol Exp Ther; 2011 Aug; 338(2):671-86. PubMed ID: 21576379
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Constitutive activities and inverse agonism in dopamine receptors.
    Zhang B; Albaker A; Plouffe B; Lefebvre C; Tiberi M
    Adv Pharmacol; 2014; 70():175-214. PubMed ID: 24931197
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Being mindful of seven-transmembrane receptor 'guests' when assessing agonist selectivity.
    Kenakin T
    Br J Pharmacol; 2010 Jul; 160(5):1045-7. PubMed ID: 20590598
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Constitutive activity and inverse agonism at the α(₁a) and α(₁b) adrenergic receptor subtypes.
    Cotecchia S
    Methods Enzymol; 2010; 485():123-38. PubMed ID: 21050914
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biased receptor functionality versus biased agonism in G-protein-coupled receptors.
    Franco R; Aguinaga D; Jiménez J; Lillo J; Martínez-Pinilla E; Navarro G
    Biomol Concepts; 2018 Dec; 9(1):143-154. PubMed ID: 30864350
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Versatility of GPCR recognition by drugs: from biological implications to therapeutic relevance.
    Bosier B; Hermans E
    Trends Pharmacol Sci; 2007 Aug; 28(8):438-46. PubMed ID: 17629964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.